These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 17395978

  • 1. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC.
    Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
    [Abstract] [Full Text] [Related]

  • 2. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC.
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [Abstract] [Full Text] [Related]

  • 3. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H, Rubinfeld H, Hadani M, Cohen ZR, Nass D, Taylor JE, Culler MD, Shimon I.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):214-8. PubMed ID: 18276067
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A.
    J Clin Endocrinol Metab; 1995 Apr 14; 80(4):1386-92. PubMed ID: 7714115
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW.
    J Clin Endocrinol Metab; 2004 Apr 14; 89(4):1577-85. PubMed ID: 15070915
    [Abstract] [Full Text] [Related]

  • 10. Some changes of receptor and postreceptor signal transduction regulated by somatostatin in pituitary hGH-secreting adenomas.
    Deng J, Shi Y, Yin J.
    Chin Med J (Engl); 1997 Sep 14; 110(9):678-81. PubMed ID: 9642323
    [Abstract] [Full Text] [Related]

  • 11. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K, Kunert-Radek J, Gruszka A, Radek M, Ławnicka H, Pawlikowski M.
    Neuro Endocrinol Lett; 2009 Mar 14; 30(1):107-10. PubMed ID: 19300395
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
    de Sá SV, Corrêa-Giannella ML, Machado MC, de Souza JJ, Pereira MA, Patzina RA, Siqueira SA, Machado MC, Giannella-Neto D.
    Endocr Relat Cancer; 2006 Mar 14; 13(1):69-78. PubMed ID: 16601280
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
    Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC.
    J Clin Endocrinol Metab; 2010 Feb 14; 95(2):968-76. PubMed ID: 19965918
    [Abstract] [Full Text] [Related]

  • 19. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture.
    Lawnicka H, Stepień H, Wyczółkowska J, Kolago B, Kunert-Radek J, Komorowski J.
    Biochem Biophys Res Commun; 2000 Feb 16; 268(2):567-71. PubMed ID: 10679244
    [Abstract] [Full Text] [Related]

  • 20. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A.
    J Clin Endocrinol Metab; 2001 Jul 16; 86(7):2976-81. PubMed ID: 11443154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.